Pyrrolo(pyrazolo)pyrimidine derivative as lrrk2 inhibitor

A compound selected from the group consisting of a compound represented by the following Formula 1, and a pharmaceutically acceptable salt, hydrate, solvate, prodrug, and isomer thereof:

• in the above formula,
• X is CH or N;
• R1 is hydrogen, halogen, or C1-4 alkyl or C1-4 alkoxy unsubstituted or substituted with one or more halogens;
• R2 is C1-6 alkyl, C1-3 alkoxy C1-6 alkyl, C3-6 cycloalkyl C1-6 alkyl, C1-6 alkoxy, C3-6 cycloalkyl, 4- to 7-membered heterocycloalkyl, or C6-10 aryl unsubstituted or substituted with one or more halogens;
• wherein the 4- to 7-membered heterocycloalkyl may be substituted with C1-4 alkyl, C1-4 alkylcarbonyl unsubstituted or substituted with one or more halogens, C3-6 cycloalkylcarbonyl, 4- to 7-membered heterocycloalkylcarbonyl unsubstituted or substituted with C1-4 alkyl, C1-4 alkylsulfonyl, C3-6 cycloalkylsulfonyl, or oxetanyl, and
• the heterocycloalkyl contains at least one atom selected from N, O, and S,
• R3 is hydrogen, halogen, or C1-4 alkyl;
• R4 is C1-6 alkyl or C3-6 cycloalkyl unsubstituted or substituted with one or more halogens;
• and
• R5 is halogen, or C1-4 alkyl unsubstituted or substituted with one or more halogens.